drugset
drugset / Trial / NCT04362670

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.

NCT04362670 ↗

Phase 1/2 Completed 153 enrolled Ocular Therapeutix, Inc.
RandomizedSequentialDouble-blindTreatment

Summary

To assess the safety, tolerability and efficacy of a single dose of OTX-CSI, a sustained release cyclosporine drug product, in subjects with dry eye disease.

Timeline

Start
2020-04-23
Primary completion
2021-08-11
Completion
2021-08-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 0.36 mg Other

Indications

dry eye syndrome